Background {#Sec1}
==========

Atrial fibrillation (AF) is a major risk factor for thromboembolic events \[[@CR1]\]. The hypercoagulability in AF is related to blood stasis, endocardial changes and abnormal blood constituents including increased markers of thrombogenesis \[[@CR2]--[@CR4]\]. The prothrombotic state in AF is adversely affected by electrical cardioversion \[[@CR5], [@CR6]\], and current guidelines recommend that anticoagulation should be continued lifelong in patients with risk factors of stroke or AF recurrence, irrespective of apparent maintenance of sinus rhythm following cardioversion \[[@CR7]\]. Whether the activation of the coagulation system persists or is attenuated after prolonged periods of sinus rhythm, remains an open question.

Haemostatic alterations as a consequence of AF are widely accepted. Intriguingly, it has recently been suggested that hypercoagulability in itself causes atrial fibrosis and thereby promotes a substrate for AF \[[@CR8]\]. AF is associated with elevated levels of prothrombin fragment 1 + 2 (F1 + 2) \[[@CR9]\]. F1 + 2 is released during the conversion of prothrombin to thrombin, whereas the endogenous thrombin potential (ETP) indicates an ex vivo potential for thrombin generation. Measurement of D-dimer reflects both thrombin generation and fibrin turnover, and may complement clinical and echocardiographic risk stratification for stroke and thromboembolism in AF \[[@CR10]--[@CR12]\]. The predictive abilities of ETP, F1 + 2 and D-dimer in foreseeing rhythm outcome after electrical cardioversion for AF have not previously been reported.

The objectives of the present investigation were twofold. First, to study the effects of sustained sinus rhythm after electrical cardioversion on levels of ETP, F1 + 2 and D-dimer, and to compare these markers in low-risk AF patients in sinus rhythm with levels measured in a reference group without AF. Secondly, we evaluated the prognostic abilities of ETP, F1 + 2 and D-dimer in foreseeing rhythm outcome 6 months after electrical cardioversion.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The present study is a substudy of the double blind, placebo-controlled Candesartan in the Prevention of Relapsing Atrial Fibrillation (CAPRAF) study \[[@CR13]\]. Briefly, 171 patients with AF were randomised to receive candesartan 8 mg once daily (*n* = 86) or placebo (*n* = 85) for 3 to 6 weeks before and then candesartan 16 mg once daily or placebo for 6 months after electrical cardioversion (Fig. [1](#Fig1){ref-type="fig"}). Patients with congestive heart failure or renal impairment were not included in the study. Cardioversion was deemed successful if sinus rhythm was established and maintained for at least 2 h (*n* = 134). Relapse of AF was defined as first electrocardiogram--recorded episode of AF. Blood samples were collected at baseline and at 6 months' follow-up. CHA~2~DS~2~-VASc score was used to stratify patients according to risk of stroke, with scores ranging from 0 to 9 and higher scores indicating greater risk. The scoring system assigns one point for each of the following; congestive heart failure, hypertension, age 65-74 years, diabetes, vascular disease or female sex, whereas age ≥ 75 years and previous stroke or transient ischemic attack count two points each. The study was approved by the Regional Ethics Committee, and all patients provided written, informed consent in accordance with the revised Declaration of Helsinki. The CAPRAF study is registered at [clinicaltrials.gov](http://clinicaltrials.gov) (NCT00130975).Fig. 1Flow chart of the CAPRAF study and reference group recruited from the ACE 1950 study. Abbreviations: ACE, Akershus Cardiac Examination 1950 study; AF, atrial fibrillation; CAPRAF study, Candesartan in the Prevention of Relapsing Atrial Fibrillation study; n, number of patients; SR, sinus rhythm

Residents of Asker and Bærum municipalities participating in a pilot for the Akershus Cardiac Examination (ACE) 1950 study were included as reference group (*n* = 49) \[[@CR14]\]. Fifty-one subjects accepted the invitation to this pilot. Two subjects were diagnosed with AF, and therefore excluded from the reference group (Fig. [1](#Fig1){ref-type="fig"}). Approval was obtained by the Regional Ethics Committee, and all patients provided written, informed consent in accordance with the revised Declaration of Helsinki. The ACE 1950 study is registered at [clinicaltrials.gov](http://clinicaltrials.gov) (NCT01555411).

Laboratory analyses {#Sec4}
-------------------

After centrifugation, citrated plasma was aliquoted and kept frozen at −70 °C until analysed. Levels of F1 + 2 and D-dimer were assessed by commercially available enzyme immunoassays; Enzygnost® F1 + 2 (monoclonal) (Siemens, Marburg, Germany) and Asserachrom® D-dimer (Stago Diagnostica). The coefficients of variation were 5.4% for F1 + 2 and 6.5% for D-dimer.

Ex-vivo thrombin generation potential was investigated by the calibrated automated thrombogram (CAT) assay, performed according to the manufacturer's instruction (Thrombinoscope BV, Maastricht, The Netherlands). The method is described in detail elsewhere \[[@CR15]\]. Briefly, platelet poor plasma was mixed with a reagent containing relipidated tissue factor and phospholipids, with the final concentrations of 5 pM and 4 μM, respectively. Reagents were provided from Thrombinoscope BV (Maastricht, The Netherlands). The reactions were performed in micro titer wells after automatic addition of a fresh made starting reagent containing CaCl~2~ (100 mM) and a thrombin specific fluorogenic substrate (Z-Gly-Gly-Arg-AMC) (2.5 mM). The fluorescence intensity was recorded by the Fluoroskan Ascent® micro plate fluorometer (Thermo Fisher Scientific Oy, Vantaa, Finland). By simultaneous analysis of an inert thrombin calibrator with known thrombin activity, the software program (Thrombinoscope BV, version 3.0.0.29) is enabled to display the ETP (nM\*min). The coefficient of variation was 5.9% for ETP.

Statistical analyses {#Sec5}
--------------------

Data are presented as mean ± standard deviation for normally distributed variables, while continuous variables not normally distributed are expressed as median (25^th^, 75^th^ percentiles). Categorical variables are shown as frequencies (%). Continuous variables were analysed by Student *t* test or the Mann-Whitney *U*-test depending on distribution. Categorical data were compared by the Chi-square test or Fischer's exact test where appropriate. The impact of continuous clinical variables and CHA~2~DS~2~-VASc score on haemostatic markers was analysed using bivariate non-parametric correlations (Spearman, correlation coefficient denoted r~s~). Kaplan-Meier curves for the probability of first recurrence of AF were plotted for medians and quartiles of baseline levels of the haemostatic markers and compared by log-rank test. Group comparisons were assessed by Mann-Whitney *U*-test. Kruskal-Wallis H test was used to compare levels of the markers according to CHA~2~DS~2~-VASc risk groups. For pairwise comparisons Bonferroni adjusted Mann-Whitney *U*-test was used. Wilcoxon's matched-pairs test was used to compare baseline and end-of-study levels of the markers. The effects of treatment with candesartan and discontinued warfarin treatment on prothrombotic marker levels were assessed with ANCOVA regression analysis on logarithmically transformed data. To investigate the impact of potential confounders on the relation between AF and the prothrombotic markers, variables related to both AF and the haemostatic indices with a *p*-value of \< 0.20 were included in a multivariate linear regression model, with logarithmically transformed marker values as the dependent variable. Medications were not included in the multivariate analysis because they were thought only to reflect the diseases that indicated their use. A two-sided *p*-value of \< 0.05 was considered statistically significant. Statistical analyses were performed with IBM SPSS Statistics for Windows, version 23.0 (IBM Corp., New York, USA).

Results {#Sec6}
=======

Baseline levels of the prothrombotic markers were available in 134 (33 women/101 men) successfully cardioverted patients (Table [1](#Tab1){ref-type="table"}). The mean age was 64 ± 11 years (range 21-84). The mean CHA~2~DS~2~-VASc score of this population was 1.5 ± 1.3 (range 0-5). The prothrombin time, expressed as the International Normalised Ratio (INR), was 2.3 ± 0.7 at baseline.Table 1Characteristics of the successfully cardioverted atrial fibrillation patientsVariable*n* = 134*Medical history* Age (years)64 ± 11 Sex (women/men)33/101 Body mass index (kg/m^2^)26 ± 4 Hypertension38 (28%) Coronary heart disease12 (9%) Diabetes10 (7%) Chronic obstructive pulmonary disease7 (5%) Current cigarette smoking21 (16%) CHA~2~DS~2~-VASc score1.5 ± 1.3*Medication at randomisation* Angiotensin receptor blocker/study drug66 (49%) Digitalis16 (12%) Beta-blockers48 (36%) Calcium channel blockers63 (47%) Diuretics11 (8%) Statins18 (13%)*Blood pressure and heart rate* Systolic blood pressure (mmHg)134 ± 18 Diastolic blood pressure (mmHg)82 ± 8 Ventricular heart rate (beats per minute)85 ± 17*Echocardiographic assessments* Left atrial systolic diameter (mm)46 ± 6 Left atrial systolic area (cm^2^)27 ± 5 Fraction of shortening (%)30 ± 7Baseline clinical characteristics of the 134 successfully cardioverted patients in the Candesartan in the Prevention of Relapsing Atrial Fibrillation (CAPRAF) study. Values presented as mean ± standard deviation or number (%). *Abbreviations*: *CHA* ~*2*~ *DS* ~*2*~ *-VASc score* A measure of stroke risk in patients with atrial fibrillation, with scores ranging from 0 to 9 and higher scores indicating greater risk, *n* Number of patients

Median baseline levels of D-dimer (357 ng/mL (226, 524)) and F1 + 2 (190 pmol/L (140, 310)) have been reported previously \[[@CR16]\]. Median baseline level of ETP was 474 nM\*min (366, 620). A correlation was seen between F1 + 2 and ETP (r~s~ = 0.594, *p* \< 0.001). D-dimer correlated to F1 + 2 (r~s~ = 0.479, *p* \< 0.001), but not to ETP (r~s~ = 0.151, *p* = 0.087).

D-dimer correlated to age (r~s~ = 0.331, *p* \< 0.001), left atrial area (r~s~ = 0.182, *p* = 0.040) and left atrial diameter (r~s~ = 0.201, *p* = 0.022) \[[@CR16]\]. Subjects with diabetes had higher levels of D-dimer; (491 ng/mL (290, 671) vs. 350 ng/mL (219, 500), *p* = 0.045). Levels of F1 + 2 correlated to left atrial area (r~s~ = 0.183, *p* = 0.039) and left atrial diameter (r~s~ = 0.193, *p* = 0.028). Levels of ETP correlated to left atrial area (r~s~ = 0.181, *p* = 0.042) and to body mass index (r~s~ = 0.194, *p* = 0.032). Females had lower levels of ETP as compared to males; (436 nM\*min (292, 526) vs. 493 nM\*min (391, 623), *p* = 0.035). CHA~2~DS~2~-VASc score correlated weakly, but significantly with baseline levels of D-dimer (r~s~ = 0.213, *p* = 0.015). An inverse correlation was observed between CHA~2~DS~2~-VASc score and baseline levels of ETP (r~s~ = −0.215, *p* = 0.014). Baseline levels of ETP were significantly higher in patients with low CHA~2~DS~2~-VASc score (0-1) as compared to patients with CHA~2~DS~2~-VASc score ≥ 3; (534 nM\*min (419, 705) vs. 417 nM\*min (276, 539), *p* = 0.011).

In order to evaluate the potential impact of sustained sinus rhythm on levels of prothrombotic markers, baseline blood samples drawn before electrical cardioversion were compared with levels at study end in patients with 6 months' survival-free of AF and with continued warfarin treatment throughout the study. The prothrombotic markers remained unchanged in the 28 patients with sustained sinus rhythm for 6 months and who were treated with warfarin till study end; D-dimer (367 ng/mL (271, 454) vs. 437 ng/mL (237, 572), *p* = 0.809), F1 + 2 (195 pmol/L (140, 350) vs. 170 pmol/L (135, 240), *p* = 0.056) and ETP (485 nM\*min (392, 653) vs. 429 nM\*min (362, 531), *p* = 0.209) (Fig. [2](#Fig2){ref-type="fig"}). Baseline levels of INR were comparable with study end levels; (2.3 ± 0.8 vs. 2.4 ± 0.5, *p* = 0.914).Fig. 2Marker levels in patients with sustained SR and continued warfarin treatment. *P*-values derived from the Wilcoxon signed-rank test. Center lines show the medians; box limits indicate the 25th and 75th percentiles; whiskers extend 1.5 times the interquartile range from the 25^th^ and 75^th^ percentiles. Abbreviations: ETP, endogenous thrombin potential; F1 + 2, prothrombin fragment 1 + 2; SR, sinus rhythm

Warfarin was discontinued in 13 AF patients after successful cardioversion (Fig. [1](#Fig1){ref-type="fig"}). These patients were younger (59 ± 12 years vs. 68 ± 9 years, *p* = 0.008), had a lower prevalence of hypertension (15% vs. 43%, *p* = 0.156) and a lower CHA~2~DS~2~-VASc score (1.2 ± 1.3 vs. 2.1 ± 1.5, *p* = 0.177) compared to those 28 AF patients who continued warfarin treatment (Table [2](#Tab2){ref-type="table"}). The time interval between warfarin discontinuation and study end was 106 ± 29 days (range 45-146). A significant rise in all markers was seen in the 13 patients who discontinued warfarin treatment; D-dimer (456 ng/mL (276, 763) vs. 304 ng/mL (165,470), *p* = 0.002), F1 + 2 (700 pmol/L (345, 845) vs. 160 pmol/L (110, 190), *p* = 0.034) and ETP (1279 nM\*min (1069, 1496) vs. 417 nM\*min (339, 494), *p* = 0.001). ANCOVA analysis comparing the changes in prothrombotic markers from baseline to study end showed significant effects of discontinued warfarin treatment in the 13 low-risk AF patients; D-dimer (*p* = 0.006), F1 + 2 (*p* \< 0.001) and ETP (*p* \< 0.001).Table 2AF patients in SR 6 months after cardioversion according to warfarin treatment at study endVariableNo warfarin (*n* = 13)Warfarin (*n* = 28)*pMedical history* Age (years)59 ± 1268 ± 90.008 Sex (women/men)4/96/220.698 Body mass index (kg/m^2^)25 ± 325 ± 20.602 Hypertension2 (15%)12 (43%)0.156 Coronary heart disease1 (8%)5 (18%)0.645 Diabetes1 (8%)00.317 Chronic obstructive pulmonary disease01 (4%)1.0 Current cigarette smoking3 (23%)2 (7%)0.307 CHA~2~DS~2~-VASc score1.2 ± 1.32.1 ± 1.50.177*Medication* Angiotensin receptor blocker/study drug6 (46%)12 (43%)0.843 Angiotensin-converting enzyme inhibitor00-- Beta-blockers3 (23%)11 (39%)0.481 Calcium channel blockers3 (23%)8 (29%)1.0 Diuretics02 (7%)1.0 Statins1 (8%)9 (32%)0.129 Antiplatelet therapy2 (15%)00.095*Blood pressure and heart rate* Systolic blood pressure (mmHg)129 ± 18140 ± 170.060 Diastolic blood pressure (mmHg)78 ± 680 ± 70.401 Ventricular heart rate (beats per minute)59 ± 758 ± 140.857Clinical characteristics of atrial fibrillation patients maintaining sinus rhythm for 6 months after electrical cardioversion with (*n* = 28) and without (*n* = 13) warfarin treatment. Values presented as mean ± standard deviation or number (%). *Abbreviations*: *AF* Atrial fibrillation; CHA~2~DS~2~-VASc score, a measure of stroke risk in patients with atrial fibrillation, with scores ranging from 0 to 9 and higher scores indicating greater risk, *n* Number of patients, *SR* Sinus rhythm

Marker values in the 13 patients in sinus rhythm at end of study were compared with corresponding values of 49 subjects in the reference group (Table [3](#Tab3){ref-type="table"}). In these 13 AF patients, D-dimer and F1 + 2 were significantly elevated compared to the reference group; D-dimer (456 ng/mL (276, 763) vs. 279 ng/mL (192, 348), *p* = 0.002) and F1 + 2 (700 pmol/L (345, 845) vs. 232 pmol/L (190, 281), *p* \< 0.001) (Fig. [3](#Fig3){ref-type="fig"}). There were no significant differences in levels of ETP; (1279 nM\*min (1069, 1496) vs. 1377 nM\*min (1204, 1509), *p* = 0.557) (Fig. [3](#Fig3){ref-type="fig"}). Hypertension was the only variable that met our criteria for potential confounders. In multivariate, linear regression analysis, AF remained the only significant determinant of both markers; D-dimer (0.50 (0.15, 0.43), *p* \< 0.001, R^2^ = 0.25) and F1 + 2 (0.60 (0.22, 0.48), *p* \< 0.001, R^2^ = 0.36).Table 3AF patients in SR with discontinued warfarin treatment at study end versus the reference groupVariableAF patients (*n* = 13)Reference group (*n* = 49)*pMedical history* Age (years)59 ± 1262 ± 00.298 Sex (women/men)4/920/290.509 Body mass index (kg/m^2^)25 ± 326 ± 40.253 Hypertension2 (15%)18 (37%)0.192 Coronary heart disease1 (8%)2 (4%)0.513 Diabetes1 (8%)4 (8%)1.0 Chronic obstructive pulmonary disease01 (2%)1.0 Current cigarette smoking3 (23%)7 (14%)0.432*Medication* Angiotensin receptor blocker/study drug6 (46%)13 (27%)0.192 Angiotensin-converting enzyme inhibitor01 (2%)1.0 Beta-blockers3 (23%)4 (8%)0.153 Calcium channel blockers3 (23%)4 (8%)0.153 Diuretics04 (8%)0.571 Statins1 (8%)11 (22%)0.431 Antiplatelet therapy2 (15%)5 (10%)0.630*Blood pressure and heart rate* Systolic blood pressure (mmHg)129 ± 18134 ± 150.326 Diastolic blood pressure (mmHg)78 ± 678 ± 80.779 Ventricular heart rate (beats per minute)59 ± 764 ± 100.072Clinical characteristics of atrial fibrillation patients maintaining sinus rhythm for 6 months without warfarin treatment at study end (*n* = 13) versus the reference group (*n* = 49).Values presented as mean ± standard deviation or number (%). *Abbreviations*: *AF* Atrial fibrillation; *n* Number of patients, *SR* Sinus rhythm Fig. 3Marker levels in patients with sustained SR and discontinued warfarin treatment compared to reference group. P-values are derived from the Mann-Whitney *U*-test. Center lines show the medians; box limits indicate the 25^th^ and 75^th^ percentiles; whiskers extend 1.5 times the interquartile range from the 25^th^ and 75^th^ percentiles. Abbreviations: ETP, endogenous thrombin potential; F1 + 2, prothrombin fragment 1 + 2; SR, sinus rhythm

None of the markers were predictive of rhythm outcome 6 months after electrical cardioversion when dichotomised by median, baseline levels; D-dimer (log rank, *p* = 0.849), ETP (log rank, *p* = 0.423) and F1 + 2 (log rank, *p* = 0.638). Kaplan-Meier analysis of quartiles of all three markers showed similar curves for survival free of AF for each quartile: D-dimer (log rank, *p* = 0.750), ETP (log rank, *p* = 0.346) and F1 + 2 (log rank, *p* = 0.586).

Treatment with candesartan had no impact on the levels of prothrombotic markers. ANCOVA analysis comparing the changes in prothrombotic markers from baseline to study end according to randomisation group showed no significant effects of candesartan (data not shown).

Discussion {#Sec7}
==========

Sustained sinus rhythm for 6 months after electrical cardioversion for AF had no impact on levels of ETP, F1 + 2 or D-dimer. Furthermore, none of the markers were predictive of rhythm outcome after electrical cardioversion. However, discontinuation of warfarin treatment in a subset of 13 low-risk patients in sinus rhythm was associated with significantly higher levels of D-dimer and F1 + 2 compared to the reference group. Thus, AF patients maintain a hypercoagulable state despite restoration and maintenance of sinus rhythm 6 months after successful cardioversion.

Angiotensin II may initiate a prothrombotic state by inducing inflammation, endothelial dysfunction and activation of platelets \[[@CR17]\]. Therefore, it is plausible that angiotensin II receptor blockers could influence on hypercoagulability. However, we found no effect of candesartan on levels of haemostatic markers in the present study.

The prothrombotic markers remained unchanged after restoration and maintenance of sinus rhythm for 6 months in patients with continued warfarin treatment throughout the study. Other studies are in line with our findings. Li-Saw-Hee et al. investigated three different markers related to thrombogenicity; namely fibrinogen, P-selectin and von Willebrand factor, and observed no changes in these markers after 3 months maintenance of sinus rhythm following cardioversion \[[@CR18]\]. Another study reports unchanged levels of D-dimer, von Willebrand factor and soluble thrombomodulin 1 month after either spontaneous restoration of sinus rhythm or pharmacological cardioversion for acute onset AF without anticoagulation treatment \[[@CR19]\]. Hence, sustained sinus rhythm seems to have little impact on the hypercoagulable state associated with AF.

We observed a rise in all three markers of hypercoagulability following discontinued warfarin treatment in 13 low-risk AF patients with sinus rhythm for 6 months. This observation is in line with previous reports of lowered levels of D-dimer, F1 + 2 and ETP by anticoagulation therapy \[[@CR20]--[@CR22]\]. Interestingly, we observed D-dimer and F1 + 2 to be significantly higher in low-risk AF patients in sinus rhythm for 6 months after cardioversion compared to a reference group without AF.

Sustained sinus rhythm did not translate into lowered procoagulant activity in our material. These findings support current risk stratification schemes in which stroke risk in AF is considered independent of whether AF is categorised into paroxysmal, persistent and permanent forms \[[@CR7], [@CR23], [@CR24]\]. Intriguingly, obtaining sinus rhythm may still be a therapeutic goal in itself, as lower risk of thromboembolism and death has been reported in paroxysmal AF forms \[[@CR25]\]. Moreover, the presence of sinus rhythm without antiarrhythmic drugs has been associated with reduced mortality \[[@CR26], [@CR27]\]. It is not clear whether the increased stroke risk associated with atrial tachyarrhythmias \[[@CR28]\] and rhythm shifts in AF \[[@CR29]--[@CR31]\] is outbalanced by a lower risk during prolonged periods of sinus rhythm \[[@CR26], [@CR27]\].

D-dimer has been shown to predict thromboembolic events, and has an additional predictive value to clinical risk scores in patients with AF \[[@CR10]--[@CR12]\]. However, none of the markers were predictive of rhythm outcome after electrical cardioversion in the present AF population. There were no differences in levels of ETP between AF patients maintaining sinus rhythm for 6 months and the reference group. Further studies are warranted to elucidate the relevance of ETP as a marker of hypercoagulability in AF patients.

Study limitations {#Sec8}
-----------------

The present study was a substudy of the CAPRAF study, and not primarily designed to test the effects of sinus rhythm restoration on markers of thrombin generation or the predictive abilities of these markers in electrical cardioversion of AF, nor was long-term electrocardiogram monitoring conducted as part of this study. Hence we cannot exclude the possibility that some of the AF subjects in sinus rhythm or some of the subjects in the reference group had asymptomatic, paroxysmal AF. Because of small numbers and demographic differences between the reference group and AF patients, our results need confirmation in larger, prospective trials.

Conclusions {#Sec9}
===========

Sustained sinus rhythm after electrical cardioversion of AF did not alter indices of hypercoagulability. In patients with AF and a low CHA~2~DS~2~-VASc score, discontinuation of oral anticoagulation was associated with a rise in D-dimer and F1 + 2 to levels significantly higher than in the reference group. Thus, our data support the current view of sustained hypercoagulability in AF patients despite long-term maintenance of sinus rhythm. Moreover, levels of prothrombotic markers were not associated with rhythm outcome after cardioversion.
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